Skip Navigation


NDT Advance Access originally published online on May 16, 2006
Nephrology Dialysis Transplantation 2006 21(7):1752-1757; doi:10.1093/ndt/gfl246
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/7/1752    most recent
gfl246v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Walz, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walz, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?

Gerd Walz

Renal Division, Freiburg, Germany

Correspondence and offprint requests to: Gerd Walz, Renal Division, University Hospital Freiburg, Hugstetter Street. 55, 79106 Freiburg, Germany. Email: gerd.walz@uniklinik-freiburg.de

Keywords: mTOR inhibitors; polycystic kidney disease; tacrolimus; vasopressin-2 receptor antagonist

The first 150 words of the full text of this article appear below.



   The new kids on the block
 
For more than three decades, autosomal dominant polycytic kidney disease (ADPKD) researchers around the globe, spurned by millions of affected patients, have tried to elucidate the mechanisms that lead to cyst formation and progression of renal failure in this heterogenetic disease. It was not until recently that realistic therapeutic interventions have come within reach. This editorial will briefly summarize the key findings that led the researchers to test vasopressin-2-receptor antagonists (V2RA) and mammalian targets of rapamycin (mTOR) inhibitors in animal models of polycystic kidney disease, and will highlight why these therapeutic avenues might be more promising and fortunate than their predecessors (Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1. Reagents that have been successfully tested in different model systems (name of known genes and proteins in parenthesis) of polycystic kidney disease.

 


   Vasopressin-2-receptor antagonists (V2RA)
 
Modern ADPKD research started when epithelial cells lining the cysts in kidneys of ADPKD patients were successfully isolated and maintained in ex vivo . . . [Full Text of this Article]



   (mTOR) inhibitors
 


   Other therapeutic approaches in ADPKD
 


   How to monitor the therapeutic efficacy in ADPKD?
 


   Is it too early to start clinical trials in ADPKD?
 


   Outlook
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
T. A. Natoli, T. C. Gareski, W. R. Dackowski, L. Smith, N. O. Bukanov, R. J. Russo, H. Husson, D. Matthews, P. Piepenhagen, and O. Ibraghimov-Beskrovnaya
Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures
Am J Physiol Renal Physiol, January 1, 2008; 294(1): F73 - F83.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
O. Ibraghimov-Beskrovnaya
Molecular pathogenesis of ADPKD and development of targeted therapeutic options
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3367 - 3370.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
E. W. Kuehn and G. Walz
Prime time for polycystic kidney disease: does one shot of roscovitine bring the cure?
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2133 - 2135.
[Full Text] [PDF]

Home page
 CJASNHome page
A. Schwarz, S. Vatandaslar, S. Merkel, and H. Haller
Renal Cell Carcinoma in Transplant Recipients with Acquired Cystic Kidney Disease
Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 750 - 756.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
C. R Lawson, T. W Doulton, and G. A MacGregor
Review: Autosomal Dominant Polycystic Kidney Disease: Role of the Renin-Angiotensin System in Raised Blood Pressure in Progression of Renal and Cardiovascular Disease
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 139 - 145.
[Abstract] [PDF]